{"analyses":[{"ciLowerLimit":"-0.252","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.180","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.1097","groupIds":["OG000","OG001"],"nonInferiorityComment":"MIRCERA treatment was regarded as non-inferior to the darbepoetin alfa reference group if the lower limit of the CI was greater than -0.75 g/dL.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","pValue":"<0.0001","paramType":"Adjusted Mean Difference","paramValue":"-0.036","statisticalMethod":"ANCOVA","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.18","value":"1.66"},{"groupId":"OG001","spread":"0.95","value":"1.69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"A time adjusted average baseline Hb concentration was calculated using the trapezoid rule from all available Hb measurements taken during the baseline period. The average evaluation period Hb concentration for each individual was calculated using the same method, from all their available measurements taken during the 2 month evaluation period (Week 21 to 28). The change in Hb concentration between the baseline and evaluation period was calculated by subtracting the baseline Hb from the evaluation period Hb. All blood samples for Hb measurements were taken prior to study drug administration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.","id":"OG000","title":"Mircera"},{"description":"Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.","id":"OG001","title":"Darbepoetin Alfa"}],"paramType":"MEAN","populationDescription":"ITT population. Here, N (number of participants analyzed)=participants evaluable for this measure. Missing data were imputed using last value carried forward.","reportingStatus":"POSTED","timeFrame":"Baseline (measurements at Week -2, Week -1 and Day 1) and Evaluation Period (Week 22, Week 24, Week 26, Week 28)","title":"Change in Hemoglobin (Hb) Concentration Between Baseline and Evaluation Period","type":"PRIMARY","unitOfMeasure":"g/dL"}